Solid clinical prospective studies investigating the association between hepatic ischemia/reperfusion injury (HIRI) and acute kidney injury (AKI) after liver transplantation are missing. HIRI, reflected by transaminase release, induces AKI in rodents, and retrospective studies suggest a similar association in humans. This prospective cohort study determined risk factors for AKI in 80 adult liver-only recipients. AKI defined by Risk, Injury, Failure, Loss, and End-Stage Kidney Disease (RIFLE) criteria developed in 21 (26%) recipients at 12 hours after reperfusion (interquartile range, 6 hours to postoperative day [POD] 1); 13 progressed from "risk" to "injury"; 5 progressed to "failure." In AKI patients, creatinine (Cr) increased during liver transplantation and was higher versus baseline at 6 hours to POD 4, whereas perioperative Cr remained stable in those without AKI. Plasma heart-type fatty acid-binding protein was higher 12 hours after reperfusion in AKI patients, though urinary kidney injury molecule 1 and neutrophil gelatinase-associated lipocalin were similar between those with or without AKI. Peak aspartate aminotransferase (AST), occurring at 6 hours, was the only independent risk factor for AKI (adjusted odds ratio, 2.42; 95% confidence interval, 1.24-4.91). Early allograft dysfunction occurred more frequently in AKI patients, and intensive care and hospital stays were longer. Patient survival at 1 year was 90% in those with AKI versus 98% in those without AKI. Chronic kidney disease stage 2 at 1 year was more frequent in patients who had had AKI (89% versus 58%, respectively). In conclusion, AKI is initiated early after liver reperfusion and its association with peak AST suggests HIRI as a determinant. Identifying operating mechanisms is critical to target interventions and to reduce associated morbidity.
Acute kidney injury (AKI) is a frequent complication after orthotopic liver transplantation (OLT). A systematic search of the literature shows reported incidences of 12%-94% in recipients of deceased donor livers (Supporting Table 1 ), depending on the definition used for AKI. Between 4.5% and 21.0% need renal replacement therapy (Supporting Table 1 ). The development of AKI after OLT, even when mild or transient, increases morbidity, mortality, and the risk of chronic kidney disease (CKD). (1) (2) (3) Although it remains unclear whether AKI after OLT is the primary driver of increased complications or is merely associative, (4) identifying risk factors of AKI is the first step in clarifying the pathophysiology and guiding prevention and treatment of the condition.
The etiology of AKI in the peritransplant period is thought to be multifactorial and is usually attributed to renal ischemia due to hemodynamic instability or drug toxicity in the peritransplant period.
(1) However, in rodents, hepatic ischemia/reperfusion injury (HIRI) has been shown to cause AKI. (5, 6) Retrospective studies also show an association between post-OLT Abbreviations: AH, anhepatic phase; AKI, acute kidney injury; AKI-F, acute renal failure; AKI-I, acute renal injury; AKI-R, acute renal risk; AST, aspartate aminotransferase; Bl, baseline; BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; CKD, chronic kidney disease; Cr, creatinine; DBD, donation after brain death; DCD, donation after circulatory death; EAD, early allograft dysfunction; eGFR, estimated glomerular filtration rate; ELISA, enzymelinked immunosorbent assay; FFP, fresh frozen plasma; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; H-FABP, heart-type fatty acid-binding protein; HIRI, hepatic ischemia/reperfusion injury; HTK, histidine tryptophan ketoglutarate; ICU, intensive care unit; IQR, interquartile range; KIM-1, aspartate aminotransferase (AST) and AKI, (7) (8) (9) (10) suggesting that HIRI plays a critical role in the pathogenesis. However, there are no solid prospective clinical studies investigating risk factors, in particular HIRI, for the development of AKI after OLT, nor is it clear at what stage of the OLT process AKI occurs.
We aimed to answer the following questions in a single-center prospective cohort study:
1. What is the earliest time point at which AKI can be diagnosed during the perioperative OLT period? 2. What are independent risk factors for AKI and is there an association with HIRI? 3. Are kidney injury biomarkers released during OLT?
Patients and Methods

PATIENT COHORT AND DATA COLLECTION
Between November 2011 and May 2014, all adult OLT candidates listed at our center were screened at the time of liver offer to be included in this prospective cohort study. Patients receiving a multiorgan transplantation, experiencing pretransplant severe renal dysfunction (defined as renal replacement therapy at time of or preceding OLT), taking part in another clinical trial, or those who did not give informed consent were excluded. Our study team, responsible for data and sample collection and processing of samples during OLT, needed to be available. Detailed donor characteristics were extracted from Eurotransplant donor charts; all other data were prospectively collected. Patients were followed for 1 year. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, was approved by our Medical Ethical Committee (s53174), and is registered (NCT01333319).
ACUTE KIDNEY INJURY
The presence of AKI was assessed by the Risk, Injury, Failure, Loss, and End-Stage Kidney Disease (RIFLE) criteria. (11) RIFLE establishes the presence of the clinical syndrome of AKI and describes the severity of this syndrome. We compared plasma creatinine (Cr) at predefined time points ( Fig. 1 ) with baseline (Bl) levels. These were used to assess the presence of AKI, established when the Cr fold change compared with Bl 1.5 (Supporting Fig. 1 ). Severity of AKI was defined by the largest Cr change observed and was classified as follows: fold change compared with Bl <1.5 was defined as normal renal function (NRF), 1.5 but <2 as acute renal risk (AKI-R), 2 but <3 as acute renal injury (AKI-I), and 3 or need for renal replacement therapy as acute renal failure (AKI-F). Serum Cr was measured in the central laboratory of the University Hospitals Leuven (Hitachi/ Roche Modular P, Roche Diagnostics, Vilvoorde, Belgium).
ANAESTHETIC AND LIVER TRANSPLANT PROCEDURES
After the application of noninvasive monitoring, anesthesia was induced with sufentanil, propofol, and cisatracurium or rocuronium. Maintenance of anesthesia was accomplished with sevoflurane and intermittent boluses of cisatracurium or rocuronium and sufentanil. A radial arterial line was placed; the internal jugular vein was cannulated for central venous pressure monitoring and volume resuscitation. Sequential cardiac output measurements (Bl, end of hepatectomy, end of kidney injury molecule 1; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; NGAL, neutrophil gelatinase-associated lipocalin; NRF, normal renal function; OLT, orthotopic liver transplantation; PNF, primary nonfunction; POD, postoperative day; PRBC, packed red blood cells; RIFLE, Risk, Injury, Failure, Loss, and End-Stage Kidney Disease; UW, University of Wisconsin; VVB, venovenous bypass.
anhepatic phase [AH], 15 minutes and 2.0 hours after reperfusion) by pulmonary artery catheter thermodilution method were performed via a Swan-Ganz catheter. Cardiac output was divided by the recipient's body surface area and cardiac indices are presented. Hemodynamic stability is managed by volume resuscitation and use of norepinephrine and dobutamine.
All patients underwent liver transplantation by caval replacement using a venovenous bypass (VVB) with both systemic and portal drainage. Reperfusion of the liver was established after completion of the portal vein with the hepatic artery anastomosed after reperfusion. The liver graft was flushed with a crystalloid solution (1-2 L) through the portal vein during the caval anastomoses. Immunosuppression was started after the arrival of the patient in the intensive care unit (ICU). Immunosuppressive therapy consisted of tacrolimus (starting with a low dose and aimed at trough levels between 5 and 8 lg/L by postoperative day [POD] 3), mycophenolate mofetil, and steroids (tapered to stop at 3 months). Induction therapy with basiliximab is not standard practice, although it is considered in case of preexisting substantial kidney dysfunction (excluded from this study), patients judged to be extremely ill upon clinical assessment and undergoing a high-risk procedure, or hepatitis C virus (HCV)-positive recipients. Depending on surgeon preference, tacrolimus introduction is delayed until POD 4 when induction therapy is given.
OUTCOME DATA
The Model for End-Stage Liver Disease (MELD) score (12) at time of transplantation was calculated from the biochemical analysis run immediately before OLT. Donor warm ischemia time in livers from donation after circulatory death (DCD) was defined as the time from withdrawal of support until cold flush of the liver. Cold ischemia time (CIT) was defined as the time between the start of cold perfusion in the donor until the liver left the ice for implantation. The implantation time starts when the liver leaves the ice and stops at portal vein reperfusion. Length of VVB, duration of surgery (from skin incision until end of wound closure), the number of packed red blood cell units, fresh frozen plasma (FFP), and platelets was collected. Peak AST was chosen to reflect HIRI. Early allograft dysfunction (EAD) was defined according to the criteria described by Olthoff et al. (13) At 1 year after OLT, renal function was assessed by an estimated glomerular filtration rate (eGFR) calculated by the 4-variable Modification of Diet in Renal Disease Study equation (14) and serum Cr values. CKD was scored according to the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation. (15) 
BLOOD AND URINE COLLECTION
Arterial blood samples were collected sequentially in ethylene diamine tetraacetic acid tubes immediately before skin incision (Bl), before hepatectomy, at the end of the AH, after reperfusion (30 minutes, 1.0 hours, 2.0 hours, 6.0 hours, and 12.0 hours), and daily thereafter until POD 5 ( Fig. 1) . After removal of the arterial line (usually > POD 1), venous blood samples were taken. Spot urine samples were collected at Bl, at the end of the AH, and after reperfusion (2.0, 6.0, and 12.0 hours; Fig. 1 ). Blood and urine were stored on ice and centrifuged (1000g, 10 minutes), aliquoted in 1-mL microtubes, and stored at -258C as soon as possible.
FIG. 1.
Prespecified time point for plasma and urine collection in the perioperative period of 80 OLTs. Plasma was taken at Bl immediately before skin incision, after hepatectomy, at the end of the AH phase immediately before the start of implantation, and postreperfusion at 0.5, 1, 2, 6, 12 hours and daily morning samples from POD 1 to 5. Urine samples were collected at Bl, and 6 and 12 hours postreperfusion.
QUANTIFICATION OF HIRI
Plasma AST, reflecting HIRI, was measured in the central laboratory of the University Hospitals Leuven (Hitachi/Roche Modular P, Roche Diagnostics) at all time points.
INJURY MARKER DETERMINATION
Urinary kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and plasma heart-type fatty acid-binding protein (H-FABP) are released from proximal tubules (KIM-1, NGAL) and distal tubules (H-FABP) upon injury. Biomarker concentrations were measured in recipients with severe AKI (AKI-I/AKI-F) and their matched NRF controls (Supporting Table 2 ). NRF controls were matched for CIT and MELD to reduce the chance of potential confounding factors influencing the analysis in this observational study.
Urinary KIM-1 and NGAL were measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (KIM-1 [human] ELISA kit, dilution 1/500, detection limit 1.279 pg/mL, Enzo Life Sciences, Lause, Switzerland; NGAL [human] ELISA KIT, dilution 1/500, detection limit 4 pg/mL, Bioporto, Gentofte, Denmark) and corrected for urinary Cr in the same sample. Plasma H-FABP was measured by ELISA according to the manufacturer's instructions (dilution 1/10, ELISA HK402, detection limit 102 pg/mL, Hycult Biotech, Uden, the Netherlands). Values below the limit of detection were replaced with a value equal to the detection limit divided by 2 to allow statistical analysis and was needed in <3% of H-FABP values and almost 50% of NGAL values.
STATISTICAL METHODS
Continuous data are presented as median (interquartile range [IQR]), and categorical variables are presented as number (%). AST was log-transformed to better approach the normal distribution. We compared continuous variables between groups at different time points with Mann-Whitney U tests. Within group differences of continuous dependent data were assessed by Friedman's test and a post hoc Dunn's. We compared categorical variables between groups with the Fisher-Freeman-Halton test and applied a Bonferroni correction in case multiple comparisons were made. To identify risk factors for AKI, logistic regression was performed. Covariates with a P value < 0.05 in the univariate logistic regressions were considered for the multivariate model. As the number of events was low, exact multivariate logistic regression models were used with a maximum of 2 covariables and in which P values were obtained with Monte Carlo simulations.
To explore the value of kidney injury markers KIM-1, NGAL, and H-FABP, we matched (1:1) recipients developing AKI-I or AKI-F to controls with NRF based on CIT and MELD using the greedy matching algorithm (macro GMATCH for SAS, version 9.2; Supporting Material, Supporting Table 2 ). Biomarker concentrations were compared using the Wilcoxon matched pairs signed rank test.
Statistical analyses were performed using SPSS, version 20 (IMB, Brussels, Belgium); StatXact-9 (Cytel, Cambridge, MA); SAS, version 9.2 (SAS Institute, Tervuren, Belgium); and GraphPad Prism, version 5.00 (GraphPad Software, La Jolla, CA). Statistical tests and confidence intervals (CIs) are 2-sided with an alpha level of 0.05.
Results
AKI IS FREQUENT AND OCCURS WITHIN HOURS AFTER REPERFUSION
During the study period, 188 OLTs were performed, and 80 recipients were included in the study (Supporting Fig. 2 shows the flowchart). All recipients received a full-sized deceased donor liver graft (13 DCD; 67 from donation after brain death [DBD] ). Donor, recipient, and surgical characteristics are outlined in Table 1 . Bl donor and recipient characteristics of patients that could not be included for logistical reasons were comparable with those of included recipients (Supporting Table 3 ). Recipients with AKI received grafts from donors that had a slightly shorter ICU stay compared with recipients with NRF (2 [1] [2] [3] days versus 3 [2-6] days; P 5 0.03). Bl Cr was comparable between those recipients who developed AKI and those who kept NRF. Graft CIT was longer for recipients who developed AKI compared with those with NRF (7.9 [6.9-9.0] hours versus 5.7 [4.8-7 .8] hours; P 5 0.004). Blood product administration during OLT and in the first 48 hours after OLT was similar in both groups. Cardiac index also did not differ between AKI patients and those with NRF at any time point (Supporting Fig. 3 ). There was no difference in the use of induction therapy or tacrolimus trough levels between the 2 groups (Table 1 and 2). Bl donor and recipient characteristics as well as occurrence of AKI in recipients receiving induction therapy did not differ from those who did not receive induction (Supporting Table 4 ). NOTE: Data are given as n (%) or median (IQR). P values denote differences between NRF and AKI. *Indications are not mutually exclusive.
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Twenty-one (26%) recipients developed AKI at a median of 12.0 hours (IQR, 6.0 hours to POD 1) postreperfusion, much earlier than usually described. In 19% of cases, the threshold for AKI was reached within 2.0 hours after reperfusion. Figure 2 shows that in AKI recipients, Cr started to increase during the OLT and Cr was higher compared with Bl as soon as 6 hours after reperfusion, at which point 38% had reached the criteria for AKI. Of those with AKI, 13 (62%, 16% of all OLT recipients) progressed from AKI-R to AKI-I at POD 2 (POD 1 to POD 2) and 5 to AKI-F (24%, 6% of all OLT recipients) at a median of POD 2 (IQR, POD 2 to POD 2; Supporting Table 5 ). In total, 4 (5%) recipients required renal replacement therapy after OLT.
Cr remained stable during the entire operative and initial post-OLT period in recipients who experienced NRF (Fig. 2) . Plasma H-FABP, a marker of distal tubular injury, (16) increased after reperfusion in recipients who developed AKI-I/AKI-F. In these patients, plasma H-FABP was significantly higher compared with their matched-controlled NRF recipients at 12 hours after reperfusion (Fig. 3) . Urinary KIM-1 and NGAL, present in the proximal tubules, (16) had similar concentrations between AKI-I/AKI-F and their matched-controlled NRF-recipients.
HIRI IS AN INDEPENDENT RISK FACTOR FOR AKI POST-OLT
In univariate logistic regression, CIT and peak AST were significantly associated with the development of AKI (Supporting Table 6 ). The use of blood products was low in this patient population (Table 2 ) and was not a risk factor.
Only peak AST was an independent risk factor for the development of AKI after OLT (Table 3) 
AKI IS ASSOCIATED WITH INCREASED MORBIDITY
Primary nonfunction (PNF) did not occur. EAD occurred in 29% of OLT and was more frequent in ICU and hospital stays were significantly longer in patients experiencing AKI (Table 2) . Patients experiencing EAD also had longer ICU stays (3 [2] [3] [4] [5] [6] [7] [8] [9] [10] days for patients with EAD versus 2 [2-4] days for patients without EAD; P 5 0.04), but hospital stay was similar (19 days for patient with EAD versus 18 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] days for patients without EAD; P 5 0.09). Graft and patient survival at 1 year after OLT was numerically lower in recipients with AKI, but this difference was not significant ( Table 2 ). The development of CKD was frequent (66%) and recipients that had experienced AKI in the first 5 days after transplantation more frequently developed CKD stage 2 or higher compared with those that had NRF (Table 2) . Although eGFR at 1 year was almost 10 mL/minute/ 1.73 m 3 lower in patients with AKI compared with NRF-recipients ( , respectively; P 5 0.72). Cr at 1 year after OLT was also not different (Table 2) .
Discussion
This prospective cohort study shows a clear association of AKI with peak AST, the only independent predictor of AKI after OLT. We also show that the development of AKI is set in motion during OLT and presents early after reperfusion. As the only solid clinical prospective study to date, its results add to those of previously performed retrospective analyses in which the frequency of perioperative AST and Cr measurements were variable and most likely not taken during OLT but in ICU settings several hours later. (7) (8) (9) (10) As expected, AKI increased morbidity with a longer ICU and hospital stay. AKI, especially severe AKI and the need for renal replacement therapy, is also a wellknown risk factor of mortality in the ICU, (17) and this has been reported in OLT as well.
(1,9) Mortality in recipients with AKI was 10% at 1 year after OLT compared with 2% in recipients with NRF, not reaching significance. Because only a small number of recipients developed severe AKI, in particular AKI-F, and very few required renal replacement therapy after OLT, a significant effect on mortality might have remained undetected. Indeed, O'Riordan et al. showed in a retrospective study that AKI-F, but not AKI-I, is a risk factor for patient death.
(1) Furthermore, the current study was conducted in a relatively low-risk population which must be kept in mind when interpreting the results. Preexisting renal dysfunction needing renal replacement therapy, a known risk factor for AKI, (17) was an exclusion criterion, as we wanted to study the effect of new, perioperative events. The low median laboratory MELD immediately before transplantation is a reflection of this low-risk population and can explain why MELD was not a risk factor for AKI. Indeed, it has been shown previously that MELD in low-risk populations is not associated with post-OLT AKI. (3) Posttransplant AKI is also a known risk factor for CKD. (18, 19) In this study, CKD stage 2 or higher was more frequent in recipients who had suffered AKI; eGFR at 1 year was almost 10 mL/minute/1.73 m 3 lower after AKI. The fact that this was not a significant difference might be a reflection of the limited number of patients in the study.
Higher-risk grafts, such as those from DCDs and older donors, tend to be more susceptible to preservation injury and have an increased risk for postoperative complications such as EAD and biliary complications. (13, 20) In 2 retrospective studies, Leithead et al. have also shown an increased occurrence of AKI after OLT with higher-risk grafts, especially in DCDs, likely because of more severe HIRI. (8) In our series, DCD donation was not associated with AKI. In DCDs, we aim to keep donor warm ischemic times and CITs very short to minimize HIRI. This is reflected by comparable peak AST in DCD and DBD grafts in this study. Most likely, HIRI in the study by Leithead et al. was much more severe than in the present study. Indeed, although our donor warm ischemia times are comparable with the study by Leithead et al. (22 [68] minutes versus 20 [69] minutes), the definition of donor warm ischemia time was not. (8) Among others in our cohort, it was defined as the time between withdrawal of support and the start of cold perfusion, while this was not the case in the study of Leithead et al. This "total warm ischemia time" is likely to be longer in the study by Leithead et al. and could account for the difference observed. (3) Likely, it is not the status of the donor per se that is most important but the severity of HIRI.
Hemodynamic instability, renal ischemia, and calcineurin inhibitors are generally believed to contribute to AKI after OLT. We cannot exclude that these, or currently unidentified possible risk factors, contributed to the development of AKI in this patient cohort. Serially measured cardiac indices during OLT were not different between recipients that developed AKI or those that had NRF. Even though cardiac indices are an accepted measure of total body and organ perfusion, we cannot rule out regional renal hypoperfusion or hypoxia in the AKI patients. Currently, there are no routinely used means to measure renal perfusion and oxygenation. Measuring central venous oxygen saturations might shed light on oxygen delivery and consumption in future studies although these reflect total body oxygenation. A post hoc analysis of mean arterial pressures and the use and dose of vasopressors and inotropes during the procedure showed no difference between patients with or without AKI (Supporting Table 7 ). Therefore, and in conjunction with the cardiac indices, it is unlikely that hemodynamic instability was a main trigger of AKI. Furthermore, Hilmi et al. found that the presence of severe hemodynamic instability at reperfusion (reperfusion syndrome) did not impact the incidence of post-OLT AKI. (3) The use of blood products (in particular total packed red blood cell and FFP transfusions) during OLT is a known risk factor for AKI. (3) We did not observe an effect of transfusion, but transfusion needs were much lower than in the study by Hilmi et al. Indeed, 35% of patients did not receive packed red blood cells (PRBC) during OLT; 20% did not receive any blood products at all with a median of 2 (0-5) units of PRBC (versus 7 [4] [5] [6] [7] [8] [9] [10] units in the study of Hilmi et al.) and 2 (0-4) units of FFP (versus 5 [2-9] units). (3) There is additional evidence that blood transfusion is a risk factor for AKI only if given in large amounts (>6 units of PRBC). (2) We did not start immunosuppressive therapyincluding the calcineurin inhibitor tacrolimus-until several hours after reperfusion, at a time when AKI had already set in. Therefore, by default, a calcineurin effect cannot have played a role in the onset of AKI. Nevertheless, the majority of recipients with AKI progressed to a more severe form of AKI (ie, AKI-I or AKI-F) during the first 2 days after OLT when tacrolimus is given and might have contributed to that progress. Nevertheless, tacrolimus trough levels were low and comparable between patients with and without AKI.
Although this observational study cannot-by its nature-confirm a causal link between HIRI and AKI, rodent studies have shown not only a direct but also a linear relationship between HIRI-as measured by transaminases-and increased renal dysfunction. (5) Despite an incomplete understanding of the pathophysiology, there are several identified important pathways. First, HIRI leads to a systemic inflammatory response as activated Kupffer cells initiate the release of circulating proinflammatory cytokines and transcription factors. We and others have shown an increase of tumor necrosis factor a, interleukin 6, and high mobility group box 1. (21) (22) (23) (24) (25) (26) Endothelial adhesion molecules in distant organs can be up-regulated by these factors and with that leukocyte recruitment and extravasation into the renal interstitial space is promoted. (22, (27) (28) (29) Activated neutrophils release enzymes and cytokines into the subendothelial space, directly causing kidney injury and the recruitment of monocytes and macrophages. (5, 22) Cytokine release from the liver after cold storage has been shown by Bezinover et al., and additional analysis revealed that the levels of cytokines were higher in grafts from higher-risk donors. (30) In a pig model, we showed that cytokine release and Kupffer cell activation was also higher in DCD livers exposed to increased warm ischemia times, resulting in increased HIRI and PNF. (31) Second, HIRI results in increased endothelial apoptosis that further promotes leukocyte infiltration. (5) Third, hepatic oxidative stress and reactive oxygen species also contribute to kidney injury. (6, 22, 26, 32) Last, the actin cytoskeleton of the tubular and renal endothelial cells might be damaged during HIRI, possibly leading to increased apoptosis. (5, 22, 33) The presence of tissue trauma to the kidney in severe AKI (ie, AKI-I/AKI-F) was confirmed by increased plasma H-FABP values, although urinary KIM-1 and NGAL concentrations were similar. This discrepancy might be the result of increased susceptibility of distal tubules to the remote effect of HIRI, as H-FABP is present in the distal tubules. It might be that plasma markers are more sensitive in the setting of remote HIRI as endothelial apoptosis is increased, possibly promoting leakage into the blood and not into urine. However, future studies focused on identifying the operating mechanisms of the apparent remote effect of HIRI on the kidney are needed to investigate this hypothesis.
Identifying the underlying mechanism might also lead to the development of preventative or treatment options. In the meantime, minimizing HIRI, eg, by keeping ischemic times short or by improving preservation by means of machine perfusion technology (34) might not only improve graft function but might also limit the remote effect of HIRI on the kidney and reduce the incidence of post-OLT AKI and the morbidity associated with AKI. Therefore, clinical trials aimed at reducing HIRI should ideally include AKI as an end point, as is increasingly the case. We recently reviewed ongoing and planned randomized controlled trials comparing machine perfusion techniques with cold storage (34) and a number of these have included AKI as a secondary end point.
Furthermore, classical perioperative renal protection strategies, including goal-directed fluid therapy, avoidance of nephrotoxic substances, etc., are invaluable in the prevention of AKI. In conclusion, this prospective, single-center cohort study shows that AKI is initiated during OLT and its association with peak AST suggests HIRI as a determinant. Future research should focus on identifying the underlying operating mechanisms that drive the association.
